

2 July 2026

DIRECTOR NOMINATION CLOSING DATE

DUNEDIN, New Zealand - Cancer diagnostics company, Pacific Edge Limited (NZX, ASX: PEB), advises that its Annual Shareholder Meeting will be held on Thursday 20 August 2026 starting at 2pm in Auckland.

For the purposes of Listing Rule 2.3.2, Pacific Edge advises that the closing date for Director nominations is Tuesday 21 July 2026. All nominations must be received by 4.00pm on the closing date.

Nominations may only be made by a shareholder entitled to attend and vote at the Annual Shareholder Meeting and must be accompanied by a consent in writing by the nominated person.

Nominations should be either emailed to investors@pacificedge.co.nz or addressed to:

Director Nominations
Pacific Edge Limited
PO Box 56
Dunedin 9016
New Zealand

Further details, including proxy voting forms and details of any Resolutions will be provided in the Notice of Meeting, which will be sent to shareholders prior to the meeting.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer

For more information:

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.